Artrya (ASX:AYA) said Dignity Health Arizona agreed to in-principle participation in the retrospective US multi-center SAPPHIRE Study, according to a Monday filing with the Australian bourse.
The study will evaluate the clinical and prognostic value of the Salix plaque analysis and its plaque dispersion score to identify patients at elevated risk of cardiovascular events, the filing said.
Additionally, the company plans to focus its upcoming study on women with coronary artery disease, which will include a group of women-only patients at risk, known as SAPPHIRE-WIN, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments